Regulation of Arthritis Severity by the Acid Sphingomyelinase
Conclusion: We identified acid sphingomyelinase as a novel druggable target in rheumatoid arthritis. Functional inhibitors of acid sphingomyelinase have been clinically used for decades, are well tolerated and suitable for long-term treatment. They would be immediately available for clinical development as a novel rheumatoid arthritis therapy.Cell Physiol Biochem 2017;43:1460 –1471
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
More News: Amitriptyline | Arthritis | Autoimmune Disease | Biochemistry | Cytology | Genetics | Physiology | Rheumatoid Arthritis | Rheumatology | Toxicology